Search: onr:"swepub:oai:DiVA.org:umu-32924" >
Effects of atenolol...
-
Boman, KurtUmeå universitet,Medicin
(author)
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
- Article/chapterEnglish2010
Publisher, publication year, extent ...
-
2009-10-13
-
SAGE Publications,2010
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:umu-32924
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-32924URI
-
https://doi.org/10.1177/1076029609349501DOI
-
https://gup.ub.gu.se/publication/108915URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVES: To compare the effects of the beta-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). DESIGN: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. RESULTS: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. CONCLUSION: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
Subject headings and genre
-
fibrinolysis
-
von Willebrand factor
-
hypertension
-
left ventricular hypertrophy
-
atenolol
-
losartan
-
MEDICINE
-
MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
-
Boman, Jenny HernestålUmeå universitet,Medicin(Swepub:umu)jeyhel99
(author)
-
Andersson, Jonas,1977-Umeå universitet,Medicin(Swepub:umu)jasaon96
(author)
-
Olofsson, Mona,1952-Umeå universitet,Medicin(Swepub:umu)mool0019
(author)
-
Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xdahbj
(author)
-
Umeå universitetMedicin
(creator_code:org_t)
Related titles
-
In:Clinical and applied thrombosis/hemostasis: SAGE Publications16:2, s. 146-1521076-02961938-2723
Internet link
Find in a library
To the university's database